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A Phase II Study of Erlotinib as Initial Treatment for Patients
with Stage IIIB–IV Non-small Cell Lung Cancer
Wallace Akerley, MD,*† Kenneth M. Boucher, PhD,* Joel S. Bentz, MD,*‡
Kylee Arbogast, BS,* and Theodore Walters, MD§
Introduction: Erlotinib improves survival in patients with advanced
non-small cell lung cancer who have been previously treated with
systemic chemotherapy. The current trial was designed to evaluate
erlotinib as a primary therapy before chemotherapy in patients with
minimally restricted eligibility criteria.
Methods: Eligibility criteria included stage IIIB/IV or recurrent
non-small cell lung cancer, no prior chemotherapy for systemic
disease, performance status  0 to 1, no history of brain metastases,
and weight loss less than 10%. Patients received erlotinib 150 mg/d
until objective or symptomatic progression when they were offered
conventional chemotherapy. The primary end point was progres-
sion-free survival.
Results: Forty patients were accrued. The median age was 65 years,
35 had performance status  1, 8 were never-smoker, and 23 were
former smokers. Histologies were adenocarcinoma in 22 and squa-
mous cell in six. The major toxicity was rash (grade 1, 12; grade 2,
16; grade 3, 3). Partial responses were observed in six (15%), stable
in 11 (28%), and progressive disease in 23 (58%). The median time
on erlotinib was 8 weeks. The median survival was 50 weeks with
1, 2, and 3 years survivals of 44%, 18%, and 16%. Retrospective
epidermal growth factor receptor mutational analysis was performed
in 18 subjects and four mutations (22%) were identified. Only 25
patients have received subsequent chemotherapy (too early, 4; re-
fused, 9; and unable because of performance status, 2), and, of these,
9 (36%) achieved unconfirmed responses.
Conclusions: Despite a modest response rate, lack of enrichment for
never-smokers and absence of conventional chemotherapy in many
patients, the median and long-term survivals were comparable with
those expected after conventional sequencing of chemotherapy.
Erlotinib as initial therapy was well tolerated and warrants random-
ized evaluation as first-line treatment for advanced lung cancer.
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Nonsmall cell lung cancer is the most frequent cause ofcancer death in the United States with a mortality of
approximately 85% for all stages based on population statis-
tics.1 Systemic chemotherapy for palliative intent with a
platinum-based doublet is the mainstay for patients with
metastatic or recurrent non-small cell lung cancer (NSCLC).
Although these treatments achieve a survival advantage and
an improvement in quality of life compared with no treatment
or a less effective control,2–4 many patients will not be treated
because of toxicity, poor performance status,5,6 or patient-
physician choice.7 Alternatives to systemic chemotherapy or
new systemic treatment strategies are needed.
Recently, erlotinib and gefitinib, both reversible, oral
inhibitors of the epidermal growth factor receptor (EGFR)
were approved for the second- or third-line treatment of
metastatic or recurrent NSCLC. Although both exhibit anti-
tumor activity demonstrated by symptom relief, antitumor
response, and tendency to induce stable disease, erlotinib was
also associated with a statistically significant improvement in
survival. In BR-21, a placebo-controlled, phase III study of
erlotinib in patients with NSCLC previously treated with one
or two prior cytotoxic chemotherapy regimens, patients
treated with erlotinib achieved an 8.9% response rate and a
43% improvement in median survival from 4.7 to 6.7
months.8 This incremental benefit in survival is at least
comparable with, or perhaps better than, second-line cyto-
toxic chemotherapy.
Retrospective evaluations to predict which subsets of
patients with NSCLC will achieve benefit from erlotinib
treatment have not yielded uniform results. Asian race, fe-
male gender, adenocarcinoma histology, a never-smoking
status, and EGFR gene mutation or amplification have been
correlated with greater chances of tumor response, but their
association with survival with the exception of never-smok-
ing status was not correlated in BR-21. In multivariate anal-
yses from a subset of these patients with adequate tissue for
analyses, adenocarcinoma, never having smoked, and over-
expression of EGFR were associated with objective re-
sponses, but survival was not influenced by the status of
EGFR expression, the number of EGFR copies, or EGFR
mutations.9 A history of never smoking remains the single
best clinical predictor of survival benefit associated with
erlotinib therapy, but those with a smoking history also
showed a survival benefit after erlotinib treatment.10 Simi-
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larly, males and patients with squamous histology also ben-
efited from erlotinib therapy.
Attempts to use these promising agents as first-line
treatment of patients with metastatic or relapsed NSCLC
were unsuccessful in a series of phase III studies in uns-
elected patients when administered in combination with con-
ventional chemotherapy.11–14 The reasons for these negative
results are unknown, but hypotheses to explain the lack of
added benefit between EGFR inhibitors and chemotherapy
include both classes benefit the same population of patients
with NSCLC; the targeted agent affects such a small fraction
of patients that its effect is diluted beyond measurement in
unselected patients; or the agents are antagonistic. Antago-
nism might explain why the progression-free survival curves
in some studies separate only during the single agent phase
after combined therapy was stopped.11,13,14 Alternatively,
EGFR inhibitors may be less effective in patients with more
rapidly growing tumors than in patients with intrinsically
more indolent tumors. Kinetic modeling of NSCLC, assum-
ing that those with more rapidly growing tumors die sooner
than those with less aggressive tumors, suggests that EGRR
inhibitors may be less effective in unselected first-line pa-
tients where a mixture of growth rates exist and more effec-
tive in patients who survive long enough to enter second-
and third-line treatment studies because those with faster
growing tumor have expired, enriching for an indolent
tumor population.15
Clinical indicators of long-term survival, which
might imply the presence of indolent tumor kinetics, have
been identified in the course of various studies. In the
untreated setting, a multivariate analysis for overall sur-
vival of patients treated with gefitinib and platinum-based
chemotherapy in two large phase III trials (INTACT 1 and
2) revealed worse survival for: performance status 2,
weight loss, bone, liver or brain metastases, and gender.16
In INTACT 2, a trend toward improved survival was
observed in patients with adenocarcinoma who had re-
ceived chemotherapy for 90 days.13 Good performance
status (ECOG 0), no appetite loss, previous surgical resec-
tion, number of metastatic sites 4, and no metastases in
liver or subcutaneous tissue have also been identified as
independent prognostic factors of survival in chemo-naive
patients treated with contemporary chemotherapy dou-
blets.17,18 Another survival model identified O2 saturation
and lung cancer symptom scale parameters (O2 saturation
90%, number of presenting major symptoms, and scores
on the appetite and fatigue subscales) as independent
prognostic factors.19 Still, other multivariate models
named brain metastases,20 inflammatory response mea-
sured by C-reactive protein,21 and pain22 as independent
prognostic factors of lesser survival. Overall, these models
predict that best survival can be anticipated from patients
with fewer symptoms, better organ function, and optimal
functional status.
The current trial was designed to evaluate the effective-
ness of erlotinib in patients with untreated advanced NSCLC
who were minimally selected based on clinical criteria.
EGFR mutations and their association with response were not
known at the time of study design. We hypothesized that
selection of patients who were likely to survive greater than
90 days based on performance status, weight loss, and ab-
sence of brain metastases would enrich for indolent tumor
characteristics that may be associated with EGFR inhibitor
responsiveness. The goal of this strategy was to provide a less
toxic, oral treatment for patients with advanced NSCLC that
could delay the time to initiation of chemotherapy and its
associated side effects, but not interfere with patients’ ability
to receive chemotherapy when needed subsequently.
PATIENTS AND METHODS
Patients
Eligible patients were required to be 18 years and older
with recurrent or stage IIIB–IV (pathology confirmed)
NSCLC, to have received no prior chemotherapy for systemic
disease (adjuvant chemotherapy allowed if 6 months from
protocol entry) and to have no poor prognostic features
defined as brain metastases, weight loss 10% in the pre-
ceding 3 months, performance status 1, or dire symptoms
necessitating immediate need for chemotherapy. Patients
were required to have measurable disease and adequate organ
function defined as liver enzymes 2 normal, bilirubin 
normal; oxygen saturation 89% on room air unless chron-
ically oxygen dependent (not cancer related); and creatinine
2.0 mg. The protocol was amended subsequently to elimi-
nate oxygen requirement. Women of childbearing potential
and sexually active males were strongly advised to use an
accepted and effective method of contraception. Pregnant or
lactating patients were ineligible. Screening tests including a
complete blood count, chemistry panel, and computed tomog-
raphy (CT) of chest and abdomen were performed before
study entry, blood work and visits were repeated monthly and
CT scans were repeated every 2 months. The study was
approved by the University of Utah, St. Luke’s Health Sys-
tem, and Montana Institutional Review Boards. All patients
signed informed consent.
Treatment
Erlotinib was administered 150 mg PO daily, repeated
every 28 days. Tablets were taken preferably in the morning
with up to 200 ml of water, 1 hour before or 2 hours after
meals. Patients who were unable to swallow tablets could
dissolve tablets in distilled water for administration.
All toxicities were graded according to the Common
Toxicity Criteria Version 3.0. For other grade 3 to 4 toxici-
ties, erlotinib was interrupted until toxicity was grade 1,
then treatment was resumed at 100 mg daily. If grade 3 to 4
toxicity recurred, erlotinib was interrupted until toxicity was
grade 1, then erlotinib was resumed at 50 mg daily. All
dose reductions were permanent.
Supportive measures consistent with optimal patient
care were provided throughout the study, including Loper-
amide to manage erlotinib-associated diarrhea, topical or oral
antibiotics, or antihistamines to manage erlotinib-associated
skin toxicity. Bisphophonates and hematopoietic factors were
allowed.
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Erlotinib treatment stopping rules were designed to
minimize the loss of patients’ performance status and to
maximize their opportunity to receive conventional chemo-
therapy subsequently. Therefore, treatment was discontinued
for either objective or subjective disease progression. Sub-
jective disease progression was implied by a one-level de-
cline in performance status; development of a new symptom
unrelated to therapy; or the doubling or rise of two consec-
utive tumor markers. If a patient was removed from protocol
treatment, the reason (including symptom if appropriate),
next planned treatment, response to first-line chemotherapy
treatment, and time to progression after chemotherapy was
reported. All patients were followed until death.
Response Evaluation
Unidimensional measurements as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) were used in
this study.23 Measurable lesions were those that could be
accurately quantified in at least one dimension as 20 mm
with conventional techniques (positron emission tomography,
CT, magnetic resonance imaging, radiograph, or physical
examination) or as 10 mm with spiral CT scan. Liver
lesions required a baseline CT scan, with responses docu-
mented by follow-up CT scans. All other lesions (or sites of
disease), including small lesions, were considered nonmea-
surable disease.
All measurements were taken and recorded in metric
notation 28 days before treatment initiation. Identical tech-
niques and methods of assessment were used to characterize
each identified and reported lesion at baseline and during
follow-up. Partial responses (PR) or complete responsewere
confirmed by repeat assessments performed 4 weeks after the
criteria for response were first met. The duration of overall
response was measured from the time that measurement
criteria were met for complete response or PR (whichever is
first recorded) until subjective or objective progression was
observed or a new treatment started.
Study records and radiologic images documenting ob-
jective response and stable disease were reviewed by the End
Point Review Panel, a subcommittee of the Huntsman Cancer
Institute’s Data, Safety and Monitoring Committee.
Statistical Analysis
The primary end point for this trial was the fraction of
patients experiencing progression-free survival after cyto-
toxic chemotherapy (PFS-CC) at 6 months. PFS-CC was
defined as the interval from study initiation until progression
of the disease after subsequent cytotoxic chemotherapy, pro-
gression of disease on erlotinib if cytotoxic chemotherapy not
initiated or death. For the study to be successful, PFS-CC had
to meet the historically observed rate of 31% based on
Southwest Oncology Group trial.6 A one-sided binomial test
at 5% nominal significance was used to calculate the maxi-
mum number of patients whose disease could progress while
on chemotherapy by 6 months (17/40 patients). For safety
reasons, interim monitoring was performed after the first 20
patients and the study would have been terminated if PFS-CC
were 25% at 6 months.
Secondary outcomes, overall survival, erlotinib-pro-
gression-free survival and chemotherapy-progression-free
survival were estimated through Kaplan-Meier methods. Sur-
vival was counted from the first dose of erlotinib.
RESULTS
Forty patients were accrued to this trial in two stages
from June 1, 2004 to 31 December, 2005. Twenty patients
were accrued during the first stage of the study and an
additional 20 patients were accrued after the safety threshold
for progression-free survival at 6 months was exceeded. The
median age was 65 years with a range from 45 to 78. The
majority of patients were male (n  25), current or former
smokers (n  32), stage IV (n  37), had a performance
status of 1 (n  35) and had adenocarcinoma (n  22). Their
characteristics are shown in Table 1.
Thirty-one patients received at least two cycles (8
weeks) of therapy. Nine patients stopped before completion
of two cycles because of objective or symptomatic progres-
sion. Nineteen completed three cycles and 16 received four or
more cycles. Four patients remain on active treatment with
erlotinib exceeding 2 years from the start of therapy. Reasons
for discontinuation of erlotinib were objective progression
(n  33), symptomatic progression (two with declining
performance status), and acute complications of cancer (pul-
monary emboli in one).
Rash and diarrhea were the most commonly observed
side effects. Five patients required a dose reduction for rash
and one patient for grade 2 bilirubin elevation. No patients
required dose reduction for diarrhea. Other toxicities that
reached grade 3 included deep vein thrombosis, diarrhea, and
mucositis. Grades 1 and 2 toxicities included fatigue, weight
TABLE 1. Patient Characteristics

















NSCLC, not otherwise specified 12
Never smokers were those smoking less than 100 cigarettes lifetime. Current
smokers were those using cigarettes within a year of study enrolment, and former
smokers were defined as those quitting for more than 1 yr.
PS, performance status; NSCLC, non-small cell lung cancer.
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loss, anorexia, and liver toxicity, as assessed by bilirubin.
Toxicity results are shown in Table 2.
All patients were included for response assessment for
erlotinib including those who received less than 8 weeks of
therapy. PR occurred in six patients (15%, 95% CI  3.9–
26.1) with a median duration that will exceed 32 months.
Stable disease occurred in 11 patients (28%, 95% CI 
14–41). The majority of patients, 23 (58%, 95% CI 42–72)
had disease progression as best response. Responses occurred
in males (n  3), smokers (three former), and nonadenocar-
cinoma (n  2). Sixteen patients had grade 2 rash and three
had grade 3 rash. Of note, there was a trend (p  0.06) for
severity of rash exceeding grade 1 to differ by smoking status
(never-smokers 63%, former 48%, and current 33%).
Twenty-five patients received subsequent cytotoxic
chemotherapy after study therapy with erlotinib. Four pa-
tients have not become eligible for secondary chemotherapy
because they remain on first-line erlotinib. Eleven patients
received erlotinib only as part of the study, but never received
subsequent chemotherapy, either because of refusal (n  9),
to inadequate performance status (n 1) or death (n 1). Of
the patients who received subsequent chemotherapy, all re-
ceived a carboplatin-based doublet. Nine (36%) had uncon-
firmed PRs, 11 (44%) had stable disease, and five (11%)
progressed after two cycles. Overall, this suggests chemotherapy
responsiveness is not diminished after erlotinib treatment.
The median progression-free time on erlotinib was 8.5
(95% CI  8.3–8.7) weeks. Patients who developed grade 0
to 1 rash discontinued erlotinib sooner than patients who
developed grade 2 to 3 rash (7.8 weeks versus 17.7 weeks,
respectively p  0.05). There was a trend for smokers
(current 7.4 weeks, former 8.0 weeks) to discontinue erlotinib
sooner than never-smokers (16 weeks, p  0.08).
The median PFS-CC defined as time on erlotinib until
progression on chemotherapy, progression on erlotinib for
those who did not receive chemotherapy or death was 27.9
weeks (95% CI  27.7–28.8). The progression-free rate at 6
months was 56%. Never-smokers had a greater chemotherapy
progression-free time than ever-smokers (42.7 versus 23.9
weeks, p  0.02).
The median survival was 50.1 weeks (95% CI 
48.5–51.7) and the 1, 2, and 3-year survivals were 44.2%,
18.2%, and 15.6%, respectively. Five patients are still alive at
this time (Figure 1). Never-smokers fared better than ever-
smokers with median survivals of 88.9 weeks (95% CI 
88.6–89.3) versus 33.1 (95% CI  32.9–33.3; p  0.04). Of
note, the median survival of patients who did not receive
conventional chemotherapy (2, too ill; 9 refused) was 13.7
weeks. Survivals were not affected by performance status,
histology, or development of rash.
Although not part of the original study design, the
protocol was amended to seek original biopsy material for
EGFR mutation analyses. Block material was available for
only two patients, but an additional 16 had material sufficient
for analysis from cytology specimens. These were analyzed
using polymerase chain reaction with melting amplicon anal-
yses followed by DNA sequencing if a mutation was identi-
fied.24 Of the 18 specimen analyzed, four (22.2%) had mu-
tations in EGFR (exon 19 (del 747) in three and exon 21
(L858R) in one. All four patients with EGFR mutations had
adenocarcinoma and three demonstrated objective responses
to erlotinib lasting 43, 97, and 100 weeks. Three were never
smokers and the fourth was a former smoker who quit 30
years before study. Two remain alive and the median survival
for those with mutations will exceed 117 weeks. Of the 14
with wild-type EGFR, there were two with response to
erlotinib, five with stable, and seven with progression. Their
median survival was 43 weeks. Of the four patients who
remained on erlotinib for more than 2 years, two had EGFR
mutations and two had wild type.
DISCUSSION
This phase II evaluation of first-line treatment with
erlotinib in minimally selected patients yielded a satisfactory
outcome with minimal toxicity. Despite a modest 15% re-
sponse rate, the median survival of 50.1 weeks and the 2-year
survival of 18% are quite comparable with studies of initial,
multiagent chemotherapy. Nineteen received at least 12
weeks of erlotinib and there was long-term tolerance with
four patients (10%) continuing to receive this agent for
greater than 2 years. Of note, only two of these latter patients
FIGURE 1. Kaplan-Meier cum survival plot for survival
(weeks) censor variable: censor sur. Time in weeks.
TABLE 2. Adverse Events (n  40)
Toxicity
Grade (N)
1 2 3 4
Deep vein thrombosis 1 1
Fatigue 6 3
Weight loss 2 2
Rash 12 16 3
Dry skin 5 3
Paronychia 2
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had EGFR mutations and two had wild type. Furthermore,
these survival results were observed in a population of pa-
tients where a large fraction did not or chose not to receive
conventional chemotherapy. Of the 25 of 40 who did receive
chemotherapy, chemosensitivity was maintained as 36%
achieved unconfirmed PRs.
It was hypothesized that early institution of erlotinib
plus minimally restrictive eligibility criteria including perfor-
mance status 0 to 1, weight loss less than 10% and absence of
brain metastases would enrich for a population that could
show greater sensitivity to erlotinib, but the response rate of
15% (95% CI 4–26) and clinical benefit rate (PR  stable)
of 42% are similar to published data for erlotinib adminis-
tered as second and third-line treatment. Although four
(22%) of 18 patients with adequate tissue demonstrated an
EGFR mutation and 20% of the patients were never-
smokers, which may be slightly greater than expected, it
does not seem that the design was successful as an enrich-
ment strategy to select for characteristics that might en-
hance erlotinib responsiveness.
The favorable results of the current trial are not unique
and are supportive of data from other trials of erlotinib as
first-line treatment for NSCLC. In one study of unselected
patients with NSCLC, 53 untreated patients with advanced
NSCLC received erlotinib as primary therapy, which resulted
in 23% response rate, median survival of 391 days and 1-year
survival of 54%.25 In another trial of similar design that was
limited to patients with age greater than or equal to 70,
erlotinib treatment yielded a 10% response rate, median
survival of 10.9 months and 2-year survival of 19%.26 Al-
though smoking history was not an eligibility criterion of
these studies, the former trial with the greater response rate
enrolled 30% never-smokers and the latter trial included only
10% never-smokers. Even more striking are studies in Asian
populations, a prognostic factor for EGFR response,27 where
response rates exceeded 50% in unselected patients,28 in
never-smokers29 and in those with EGFR mutations.30 In
contrast, a study evaluating the effectiveness of first line
therapy for erlotinib for patients with performance status  2
has shown lesser outcomes with response rates of 2%31
suggesting that poor performance may define a population of
patients who may not benefit from erlotinib as first-line
therapy.
One unanticipated finding of this study was the rela-
tively large fraction of patients who agreed to participate in
the trial with the understanding that they would receive
conventional chemotherapy after erlotinib but subsequently
refused after erlotinib progression. Review of these patients
versus those who did receive chemotherapy was not substan-
tially different in terms of performance status, erlotinib tox-
icity, and response to erlotinib. Anecdotally, some stated that
they participated in the trial because it offered an alternative
to conventional chemotherapy and would have chosen no
therapy had this trial not existed. It would be of interest to
determine what fraction of “fit” patients with lung cancer
and/or their physicians avoid seeking medical oncology con-
sultation because of “antichemotherapy” biases.
In summary, minimally selected patients treated with
erlotinib as initial therapy for metastatic NSCLC seem to
achieve similar survival with less toxicity than expected with
conventional chemotherapy. The strategy of initial treatment
with erlotinib followed by subsequent chemotherapy is sup-
ported by multiple studies and a randomized trial compared
with conventional chemotherapy is warranted to test this
hypothesis. This alternative approach may appeal to a broader
population of patients than are currently receiving therapy by
including those with a fear of chemotherapy. Some minimal
patient enrichment criteria such as performance status limited
to 0 to 1 would be necessary to ensure that patients are able
to withstand ineffective therapy in either arm and allow
crossover to second-line treatment. Additional tactics to en-
hance selection of patients who might derive greater benefit
from erlotinib and thus improve the chances of a positive
study or reduce the number of patients include EGFR anal-
ysis, other biomarkers, prior cigarette exposure, gender, race
and/or conditional rash assessment but are not a necessary
requirement.
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